146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care.

Looking for more dementia and Alzheimer disease discussion? Check out the NeurologyLive® Dementia and Alzheimer disease clinical focus page.

Episode Breakdown:

• 1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk
• 2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6
• 6:00 – What clinicians should know about patient risk and genotype testing
• 8:00 – Neurology News Minute
• 10:10 – Clinical implications of the updated label, including risk-benefit conversations
• 13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients
  
  

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies

• FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths

• AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.